Introduction
AI Overview · plain answer
Lu-177 PSMA rechallenge means giving a second course of Lu-177 PSMA therapy to a man whose prostate cancer responded to an initial course and then progressed after a treatment break — provided the cancer is still PSMA-positive on a repeat PSMA-PET scan. In pooled studies, about 45% of selected patients had a PSA fall of more than 50%, and about 71% had some PSA fall, with severe (grade 3+) side effects in roughly 14%. It is reserved for carefully selected patients, and responses are usually not as deep or durable as the first time.
One of the most common questions after a successful course of Lu-177 PSMA therapy is: “If it worked before, can I have it again if the cancer comes back?” It is a fair question, and a growing body of evidence supports doing exactly that in the right patient. But “the right patient” is the key phrase — rechallenge is not automatic, and one scan in particular decides whether it makes sense.
Important
This is general medical information for education, not medical advice. The response rates below are pooled averages from selected cohorts and ongoing research — they are not a prediction for any one person. Whether rechallenge is appropriate depends on an individual’s prior response, a repeat PSMA-PET scan, blood counts and kidney function, and is decided in a multidisciplinary review.
What “rechallenge” actually means
In oncology, rechallenge has a precise meaning: a patient who relapses after an initial response, having stopped the treatment, is re-treated with the same therapy — usually the same dose and schedule — after a treatment-free interval.[4] For Lu-177 PSMA this means a man completed his initial course (commonly four to six cycles), responded, took a break, and later showed renewed progression.
It helps to distinguish two different strategies used in men who respond to Lu-177 PSMA:[3]
- Extended (continuous) therapy — continuing cycles beyond the standard six without a break, for a patient who is responding but still has a high residual PSMA-positive tumour burden.
- Rechallenge — readministering Lu-177 PSMA after a treatment-free interval, for a patient whose disease had reduced considerably and then recurred. A break of at least four months is often used to define a genuine rechallenge rather than a scheduling delay.[7]
This article is about the second strategy — re-treating after a break.
Who is a candidate — and the one scan that decides it
Across the published cohorts, candidates for Lu-177 PSMA rechallenge share a consistent set of features:[4][5]
| Criterion |
What it means |
| Good initial response |
Completed the first Lu-177 PSMA course with a clear response — typically a PSA fall of at least 50% and reduced uptake on PSMA-PET |
| A treatment break, then progression |
Disease was controlled for a period, then progressed (rising PSA / new activity) after a treatment-free interval |
| Still PSMA-positive |
A repeat PSMA-PET scan confirms the cancer still strongly expresses PSMA — the single most important gate |
| Good fitness |
Performance status ECOG 0–1 |
| Adequate organ reserve |
Recovered bone-marrow function (haemoglobin, platelets, white cells) and adequate kidney function, with no serious prior toxicity |
The decisive step is the repeat PSMA-PET. Lu-177 PSMA only works on cancer that carries the PSMA target. Some prostate cancers lose PSMA expression over time, or develop PSMA-negative areas that have effectively “escaped.” If the repeat scan shows the disease is no longer PSMA-positive, rechallenge will not help — and the patient is better served by a different treatment. This is why a man cannot simply ask for “more Lu-177”; the scan has to earn it first.
How well does it work the second time?
The evidence is encouraging but should be read with care, because it comes from selected patients. A 2025 systematic review and meta-analysis pooled 11 studies and 307 patients who received Lu-177 PSMA rechallenge:[1]
- A PSA fall of more than 50% in about 45% of patients (95% CI 36–54%).
- Any PSA fall in about 71% of patients (95% CI 61–80%).
In a well-known prospective cohort, rechallenge produced a PSA50 response in 73% of patients (11 of 15), compared with just 19% for other systemic therapies given at the same stage — suggesting that, in men who responded the first time and remain PSMA-positive, repeating Lu-177 PSMA can outperform a switch to a different drug.[2] Men who achieve a PSA50 response on rechallenge have had a median overall survival of around 19 months from the start of rechallenge, and cumulative survival from the very first cycle of the initial course has reached up to roughly 40 months in some cohorts.[3][4]
An honest caveat
Rechallenge responses are generally not as deep or as durable as the first course, and rechallenge usually involves fewer cycles (often around two). These figures are averages in carefully chosen patients, not a guarantee for any individual — and most of the data are retrospective.
Is it safe to give the radiation again?
Reassuringly, the safety of rechallenge has been broadly similar to the first course.[4] In the pooled meta-analysis, grade 3-or-higher side effects occurred in about 14% of patients, and dry mouth (xerostomia) on rechallenge was mild-to-moderate (grade 1–2) in about 43%, with no severe (grade 3+) cases reported.[1]
The considerations that change with a second course are about cumulative dose:
- Bone marrow — anaemia and low platelets are the most common higher-grade effects, and the marrow has already received radiation from the first course, so blood counts must have recovered and are watched closely.[3]
- Kidneys — the kidneys clear the radioligand and receive dose over both courses, so kidney function is monitored; high-grade renal toxicity has been uncommon (about 7.4% in one series).[4]
- Salivary glands — dry mouth can occur again but is typically mild and managed supportively.[1]
In other words, the second course is not a free pass — it is given because the marrow and kidneys have recovered enough to tolerate the added dose, which is exactly what the pre-rechallenge assessment confirms.
Rechallenge, extended therapy, or switch? Side by side
| Approach |
Best suited to |
| Rechallenge Lu-177 PSMA |
Responded to the first course, took a break, then progressed — and is still PSMA-positive on a repeat scan |
| Extended / continuous Lu-177 PSMA |
Still responding but with high residual PSMA-positive disease after six cycles — continue without a break |
| Switch to another therapy |
No longer PSMA-positive, or not eligible for more radiation — e.g. chemotherapy, a PARP inhibitor (if an HRR/BRCA mutation is present), radium-223 for bone-predominant disease, or an alpha-emitter (Ac-225) PSMA therapy in some centres |
These are not ranked from best to worst; they answer different clinical situations. The repeat PSMA-PET, the pattern of progression and the patient’s organ reserve usually point clearly to one of them.
What is still being studied
Most rechallenge data are retrospective, from single centres and small cohorts, which is why the field is moving toward prospective evidence. RE-LuPSMA, a phase 2 prospective trial, is formally testing retreatment: patients must again meet PSMA-PET criteria before rechallenge and may receive up to six further cycles, with 12-month survival from the start of rechallenge as the primary measure.[6] Open questions that remain include the best patient-selection thresholds, how to account for cumulative marrow and kidney dose, and how to standardise protocols between centres.[3] Until those are settled, rechallenge is best offered within an experienced theranostics service that can weigh these factors case by case.
"The question is never simply ‘can we give Lu-177 again?’ It is ‘does the repeat PSMA-PET still show the target, and have the marrow and kidneys recovered enough to do it safely?’ When the answer to both is yes, rechallenge is one of the more rewarding things we do."
Dr. Ishita B. Sen · Director & Chief, Nuclear Medicine, FMRI
Second Read · review of your prior therapy
If you or a family member had Lu-177 PSMA therapy before and the cancer is progressing again, the nuclear medicine team at FMRI — Dr. Ishita B. Sen and Dr. Dharmender Malik — can review the earlier response, the latest PSMA-PET and blood work, and advise whether rechallenge is a realistic option or whether another route fits better.
Request a Second Read · WhatsApp +91 8800 988936
For patients & families
Frequently asked questions
Q01What is Lu-177 PSMA rechallenge?
Rechallenge means giving a second course of Lu-177 PSMA radioligand therapy to a man whose metastatic castration-resistant prostate cancer responded to an initial course, then progressed after the course was completed and a treatment-free interval had passed. The same therapy is given again, provided the cancer is still PSMA-positive on a repeat PSMA-PET scan. It is different from continuing (extended) therapy without a break.
Q02Can you have Lu-177 PSMA therapy more than once?
Yes, in selected patients. Men who had a good response to an initial Lu-177 PSMA course and later progressed can sometimes be re-treated. In a meta-analysis of rechallenge studies, about 45% of patients had a PSA fall of more than 50% and about 71% had some PSA fall on rechallenge. It is not automatic — it depends on a repeat PSMA-PET still showing PSMA-positive disease, adequate blood counts and kidney function, and good overall fitness.
Q03Who is a candidate for Lu-177 PSMA rechallenge?
Typical criteria are: a completed initial Lu-177 PSMA course with a clear response (a PSA fall of at least 50% and reduced uptake on PSMA-PET); progression after a treatment-free interval; a repeat PSMA-PET confirming the disease is still PSMA-positive; good performance status (ECOG 0–1); and adequate bone-marrow and kidney function with no serious prior toxicity. The decision is made in a multidisciplinary review.
Q04How well does Lu-177 PSMA work the second time?
In pooled data from rechallenge studies, about 45% of selected patients achieved a PSA fall of more than 50% and about 71% had some PSA fall. In one prospective cohort, rechallenge produced a PSA50 response in 73% of patients, compared with 19% for other systemic therapies at the same stage. Men who achieve a PSA50 response on rechallenge have had a median overall survival of around 19 months from the start of rechallenge. Responses are generally not as deep or durable as the first course, and these are averages in selected patients, not guarantees.
Q05Why do I need another PSMA-PET scan before rechallenge?
Lu-177 PSMA only works on cancer that carries the PSMA target. Over time, some prostate cancers lose PSMA expression or develop PSMA-negative areas, which would not respond to the therapy. A repeat PSMA-PET scan confirms the disease is still PSMA-positive before rechallenge, and helps rule out PSMA-negative progression that would be better treated another way.
Q06Is Lu-177 PSMA rechallenge safe the second time?
The safety profile is broadly similar to the first course. In pooled data, grade 3 or higher side effects occurred in about 14% of patients, and dry mouth on rechallenge was mild-to-moderate (grade 1–2) in about 43% with no severe cases. The main concerns are cumulative effects on the bone marrow (anaemia, low platelets) and the kidneys, so blood counts and kidney function are monitored carefully because of the added radiation dose over two courses.
Q07How long after the first course can rechallenge be given?
There is no fixed rule, but rechallenge follows a treatment-free interval — typically several months to about a year after the initial course. In studies the interval has commonly been around 5 to 9 months. A break of at least 4 months is often used to distinguish a genuine rechallenge from a simple scheduling delay. The timing is guided by when the disease progresses and the patient's recovery of blood counts.
Q08What if my cancer is no longer PSMA-positive?
If a repeat PSMA-PET shows the disease is no longer PSMA-positive, Lu-177 PSMA rechallenge is unlikely to help, and other options are considered instead — such as chemotherapy, a PARP inhibitor (if there is a relevant gene mutation), radium-223 for bone-predominant disease, or, in some centres, an alpha-emitter PSMA therapy (Ac-225). The right alternative depends on the individual's disease and prior treatment.
Evidence & references
Figures in this article are taken from the following peer-reviewed studies and a systematic review. Open each in a new tab to read the source.
[1] Efficacy and safety of rechallenge therapy with [177Lu]Lu-PSMA in mCRPC: a systematic review and meta-analysis (11 studies, 307 patients).
PubMed. 2025.
View source ↗[2] Violet J, Sandhu S, Iravani A, et al. Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Phase II Trial of 177Lu-PSMA-617.
J Nucl Med. 2020;61:857-865.
View source ↗[3] Rechallenge and Extended [177Lu]Lu-PSMA Therapy in Metastatic Prostate Cancer (review).
J Nucl Med. 2025.
View source ↗[4] Efficacy and safety of rechallenge with [177Lu]Lu-PSMA-I&T radioligand therapy in mCRPC.
Eur J Nucl Med Mol Imaging. 2024.
View source ↗[5] Early Experience of Rechallenge 177Lu-PSMA Radioligand Therapy After an Initial Good Response.
J Nucl Med. 2019;60(5):644.
View source ↗[6] RE-LuPSMA — Phase 2 Prospective Trial of Retreatment with [177Lu]Lu-PSMA-617.
J Nucl Med. 2026.
View source ↗[7] Safety and Efficacy of Extended Therapy with [177Lu]Lu-PSMA: A German Multicenter Study.
J Nucl Med. 2024;65(6):909.
View source ↗[8] VISION — Sartor O, de Bono J, Chi KN, et al. Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.
N Engl J Med. 2021;385(12):1091-1103.
View source ↗
About the Author
Dr. Ishita B. Sen
MBBS · MD (Nuclear Medicine) · Director & Chief, Department of Nuclear Medicine, Fortis Memorial Research Institute
Dr. Sen leads the nuclear medicine and theranostics programme at FMRI, Gurugram, with a focus on PSMA and DOTATATE imaging and Lu-177 and Ac-225 radioligand therapy. She works alongside Dr. Dharmender Malik on patient selection, dosimetry and re-treatment decisions in advanced prostate cancer.